Comparison of levocetrizine and bilastine for treatment of childhood transient red itchy skin rash

Comparison of the efficacy and safety of levocetrizine vs bilastine for treatment of chronic idiopathic urticaria in pediatric population: an observer blinded randomised control trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/02/040106

Enrollment

Registered

2022-02-08

Start date

Unknown

Completion date

Unknown

Last updated

2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L501- Idiopathic urticaria

Interventions

Intervention1: TAB BILASTINE 20 mg : All the patients meeting the eligibility criteria, presenting to department of Skin and VD will be included. After randomization into group A, they will receive OR

Eligibility

Inclusion criteria

Inclusion criteria: I. All patients of age 6 to 16 years II. Clinically diagnosed chronic spontaneous urticaria(Wheals present on most days of the week for >= 6 weeks) with or without angioedema.

Exclusion criteria

Exclusion criteria: I. Hepatic and renal impairment II. Autoimmune comorbidity III. Endocrine abnormality IV. Prior treatment with antihistamines and steroids within a week V. Failure to follow up

Design outcomes

Primary

Measure	Time frame
To assess and compare the efficacy of Levocetrizine and Bilastine in pediatric urticaria.Timepoint: End of 4 months	—

Secondary

Measure	Time frame
To assess and compare the safety profile of Levocetrizine and Bilastine in pediatric urticaria.Timepoint: End of 4 months	—

Countries

India

Contacts

Public ContactDebashree Sahoo

IMS and SUM Hospital

pandamaitreyee@gmail.com9437218952

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026